A human beta cell line with drug inducible excision of immortalizing transgenes. by Benazra, Marion et al.
A human beta cell line with drug inducible excision of
immortalizing transgenes.
Marion Benazra, Marie-Jose´ Lecomte, Claire Colace, Andreas Mu¨ller, Ce´cile
Machado, Se´verine Pechberty, Emilie Bricout-Neveu, Maud Grenier-Godard,
Miche`le Solimena, Raphae¨l Scharfmann, et al.
To cite this version:
Marion Benazra, Marie-Jose´ Lecomte, Claire Colace, Andreas Mu¨ller, Ce´cile Machado, et al..
A human beta cell line with drug inducible excision of immortalizing transgenes.. Molecular
metabolism, Elsevier, 2015, 4 (12), pp.916-925. <10.1016/j.molmet.2015.09.008>. <inserm-
01298792>
HAL Id: inserm-01298792
http://www.hal.inserm.fr/inserm-01298792
Submitted on 6 Apr 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

Original articleA human beta cell line with drug inducible
excision of immortalizing transgenesMarion Benazra 1,2,3,4, Marie-José Lecomte 5, Claire Colace 1,2,3,4, Andreas Müller 6,7, Cécile Machado 5,
Severine Pechberty 5, Emilie Bricout-Neveu 5, Maud Grenier-Godard 5, Michele Solimena 6,7,8,
Raphaël Scharfmann 9, Paul Czernichow 5, Philippe Ravassard 1,2,3,4,*ABSTRACT
Objectives: Access to immortalized human pancreatic beta cell lines that are phenotypically close to genuine adult beta cells, represent a major
tool to better understand human beta cell physiology and develop new therapeutics for Diabetes. Here we derived a new conditionally
immortalized human beta cell line, EndoC-bH3 in which immortalizing transgene can be efﬁciently removed by simple addition of tamoxifen.
Methods: We used lentiviral mediated gene transfer to stably integrate a tamoxifen inducible form of CRE (CRE-ERT2) into the recently developed
conditionally immortalized EndoC bH2 line. The resulting EndoC-bH3 line was characterized before and after tamoxifen treatment for cell
proliferation, insulin content and insulin secretion.
Results: We showed that EndoC-bH3 expressing CRE-ERT2 can be massively ampliﬁed in culture. We established an optimized tamoxifen
treatment to efﬁciently excise the immortalizing transgenes resulting in proliferation arrest. In addition, insulin expression raised by 12 fold and
insulin content increased by 23 fold reaching 2 mg of insulin per million cells. Such massive increase was accompanied by enhanced insulin
secretion upon glucose stimulation. We further observed that tamoxifen treated cells maintained a stable function for 5 weeks in culture.
Conclusions: EndoC bH3 cell line represents a powerful tool that allows, using a simple and efﬁcient procedure, the massive production of
functional non-proliferative human beta cells. Such cells are close to genuine human beta cells and maintain a stable phenotype for 5 weeks in
culture.
 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords Cell engineering; Human pancreatic beta cell line; Conditional immortalization; Tamoxifen inducible CRE; Human beta cell function1. INTRODUCTION
Type 1 diabetes results from the destruction of insulin-producing
pancreatic beta cells by a beta cell-speciﬁc autoimmune process
while type 2 diabetes results from the combination of insulin resistance
and inadequate insulin secretion. Thus, for both types of diabetes,
functional beta cell mass is not sufﬁcient for appropriate glycemic
control. Therefore understanding beta cell physiology and function is a
critical issue for understanding diabetes and developing innovative
therapeutic solutions. Rodent beta cells have been used so far and
were instrumental for acquiring important basic knowledge of beta cell
function. However, data generated with such cells cannot easily be
translated to humans since major species differences have been re-
ported [1,2]. Thus, access to human beta cells is crucial to progress in
understanding human speciﬁc beta cell function and, unfortunately,
scarcity of organ donors makes it necessary to search for other
sources [3].1Institut du cerveau et de la moelle (ICM), Biotechnology & Biotherapy Team, 75013 P
France 4Université Pierre et Marie Curie, 75013 Paris, France 5Endocells, Pépinière d’en
Institute of the Helmholtz Center Munich at the University Hospital and Faculty of Medic
(DZD e.V), 85764 Neuherberg, Germany 8Max Planck Institute of Molecular Cell Biology
Médecine, Université Paris Descartes, Sorbonne Paris Cité, 75014 Paris, France
*Corresponding author. ICM Biotechnology & Biotherapy Team, Hôpital Pitié Salpêtrièr
E-mail: philippe.ravassard@upmc.fr (P. Ravassard).
Received June 26, 2015  Revision received September 17, 2015  Accepted Septem
http://dx.doi.org/10.1016/j.molmet.2015.09.008
916 MOLECULAR METABOLISM 4 (2015) 916e925  2015 The Authors. Published by ETo develop such alternative sources, large efforts have been under-
taken to differentiate human embryonic or induced pluripotent stem
cells (hESCs/iPSCs) towards pancreatic mature endocrine cells. Since
the important original contribution of the Viacyte group to generate
endocrine cells from hESCs [4,5], recent advances have been made in
this ﬁeld to obtain in vitro more fully mature pancreatic endocrine cells
[6,7]. Still, both the production yield and the robustness of the process
need to be further improved. Using an approach based on targeted
oncogenesis in human fetal pancreas, we generated the ﬁrst immor-
talized human beta cell line, referred as EndoC-bH1, giving access to
unlimited number of functional human beta cells [8]. Although, this line
is similar to primary adult human beta cells, it is continuously prolif-
erating, which represents a major difference with mature beta cells
that that have a low proliferation rate [9]. We recently reported the
production of the second generation of human beta cell line, referred to
as EndoC-bH2 that was conditionally immortalized. In this cell line,
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transcriptase (hTERT), used as immortalizing transgenes, can be
removed by CRE mediated excision [10]. We have shown that
constitutive expression of CRE in EndoC-bH2 cells resulted in drastic
proliferation arrest and enhancement of beta cell function both at the
level of insulin content and secretion upon glucose stimulation. Thus,
excised EndoC-bH2 cells are highly representative of human primary
beta cells.
In previous studies [10], we transduced EndoC-bH2 cells with a len-
tiviral vector expressing CRE that efﬁciently excised immortalizing
transgenes in more than 95% of cells. Although such an approach is
efﬁcient, mass production of excised cells that would require massive
amounts of viral vectors cannot be easily achieved. Therefore, to
circumvent this limitation, we devised a drug-activated excision
strategy coupled with antibiotic selection.
Many drug-inducible systems have been used to control gene
expression both in vitro and in vivo [11e14]. We selected here the one
based on CRE-ERT2 fusion protein [15]. CRE-ERT2 has high afﬁnity for
the 4-hydroxytamoxifen (TAM) but not for the endogenous estradiol.
Therefore, the recombinase activity of CRE-ERT2 is dependent on the
addition of this compound to the culture medium. After its exposure to
the speciﬁc inducer TAM, CRE-ERT2 is translocated from the cyto-
plasm into the nucleus and excises loxP-ﬂanked DNA regions.
In the present study, we stably modiﬁed EndoC-bH2 excisable line by
lentiviral vector-mediated gene transfer to integrate both CRE-ERT2
and a constitutive puromycin selection marker. The resulting line,
EndoC-bH3, was selected and massively expanded in vitro in the
presence of puromycin. TAM dose and duration of treatment were
optimized to achieve efﬁcient immortalizing transgene excision. TAM
mediated excision resulted in a sharp decrease of EndoC-bH3 cell
proliferation and pronounced enhancement of beta-cell speciﬁc fea-
tures such as insulin expression, storage in secretory granules and
glucose stimulated secretion. These properties were maintained in
culture for several weeks. Importantly, by opposition to the previous
EndoC-b2 cells, the massive production of this cell line in its excised
state is simple, giving access to large-scale drug discovery, prolifer-
ation studies and development of preclinical models.
2. MATERIALS AND METHODS
2.1. Lentiviral vectors and cell transduction
A tamoxifen inducible form of CRE (CRE-ERT2) was cloned down-
stream of the CMV promoter in a lentiviral backbone. Brieﬂy, LR clo-
nase II recombination was performed using pTrip CMV rfa-Gateway
Delta U3 destination [16] vector and pENTR/D/TOPOeCre-ERT2 entry
clone. The Cre-ERT2 fragment was ampliﬁed by PCR from a plasmid
kindly provided by Guilan Vodjdani (INSERM UMR1141) using the
forward primer 50CACCGGTACCCTCGAGATCGAT30 and reverse primer
50TCAAGCTGTGGCAGGGAAACC30, and the resulting PCR product was
cloned into the pENTR/D/TOPO plasmid to generate the Cre-ERT2 entry
clone.
The pTrip PGK puro polyA/CMV CRE-ERT2 Delta U3 was generated
using pTrip CMV CRE-ERT2 Delta U3 as backbone in which a PGK
puromycin resistance polyA was inserted in the reverse orientation on
the 50 side of the triplex sequence. Brieﬂy, a linker containing EcoRI-
compatible SacII, SalI BamHI MluI and EcoRI restriction sites was
ﬁrst inserted in the EcoRI site of pTrip CMV CRE-ERT2 Delta U3. Next,
the polyA signal from human beta globin was ampliﬁed by PCR from
pCDNA3.0 vector (Invitrogen) with primers containing SacII and SalI
overhanging ends, and the resulting PCR product was cloned in the
integrated linker sequence between SacII and SalI sites. The PGK
promoter sequence was digested from pTrip PGK eGFP Delta U3 vectorMOLECULAR METABOLISM 4 (2015) 916e925  2015 The Authors. Published by Elsevier GmbH. This is an o
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Finally, the puromycin resistance gene was ampliﬁed by PCR from
pLKO puro vector (Addgene) with primers containing BamHI and SalI
overhanging ends and the resulting PCR product was cloned between
the PGK promoter and the polyA sequences in the corresponding re-
striction sites. Lentiviral vector stocks were produced by transient
transfection of 293T cells with the p8.91 encapsidation plasmid,
pHCMV-G, encoding the vesicular stomatitis virus (VSV) glycoprotein-G
and the pTRIP DU3 as previously described [18].
EndoC-bH2 cells were transduced with pTrip PGK puro polyA/CMV
CRE-ERT2 Delta U3 to generate EndoC-bH3 cells using a total amount
of viral particles of 30 ng of p24 capside protein per 105 cells in the
presence of 10 mg/ml DEAE-dextran as described elsewhere [18].
2.2. Cell line culture and excision process
EndoC-bH3 cells were cultured in DMEM containing 5.6 mM glucose,
2% BSA fraction V, 50 mM 2-mercaptoethanol, 10 mM nicotinamide,
5.5 mg/ml transferrin, 6.7 ng/ml sodium selenite, Penicillin (100 units/
ml)/Streptomycin (100 mg/ml). Ten mg/ml of puromycin (selective
antibiotic) were added extemporaneously in the complete medium.
Cells were seeded onto matrigel- and ﬁbronectin-coated culture plates
at 4  106 cells/plate. Passage was performed every week. Inducible
excision of CRE mediated immortalizing transgenes was performed
with addition of TAM, 1 mM unless specify in the text.
Cells were counted according to manufacturer instructions using the
ADAM-MC automatic cell counter instrument (NanoEnTek Inc. Seoul
Korea).
2.3. Immunostaining
For immunocytochemistry, EndoC-bH3 cells were treated with TAM for
14 days. They were next seeded on 12-mm matrigel/ﬁbronectin glass
coated coverslips and further cultured with TAM for 7 days. Next, the
cells were ﬁxed for 1 h in 4% paraformaldehyde. The following anti-
bodies were used for immunostaining: guinea pig anti-insulin antibody
(1/500, DakoCytomation, A0564) and mouse anti-SV40LT (1/50, Cal-
biochem Merck Biosciences, DP-02). The secondary antibodies were
ﬂuorescein anti-mouse antibody (1/200, Immunotech, IM0819) and
Texas-red anti-guinea pig antibody (1/200; Jackson Immunoresearch
Laboratories, 706-076-148). Nuclei were stained with Hoechst 33342
ﬂuorescent stain (Life Technologies). Digital images of cells were
captured using an Olympus Fluoview FV1000 confocal microscope.
2.4. Cell proliferation assays
Cell proliferation analysis was conducted using Click-iT EdU Alexa
Fluor 647 Flow Cytometry Assay Kit (Life Technology). Brieﬂy, EdU was
added into cell-culture medium to a ﬁnal concentration of 10 mmol/l
one hour before the endpoint of the experiments. Cells were collected
after trypsin treatment, washed once with 2 ml of 1% BSA in PBS, ﬁxed
using Click-iT ﬁxative, and incubated for 15 min in saponin-based
permeabilization solution. Cells were then treated with Click-iT reac-
tion cocktail, according to manufacturer’s instruction, for 30 min
before ﬂow cytometry analysis. DAPI (1 mM) (FxCycle Violet Stain; Life
Technologies) was added directly before FACS analysis. Data were
acquired on an LSRFortessa (BD Biosciences) and analyzed with FACS
Diva software (BD). A total of 50,000 events were collected for the cell
proliferation analysis.
2.5. RNA isolation, reverse transcription and RT-PCR
Total RNA was isolated from EndoC-bH3 cell line using the RNeasy
microkit (Qiagen), as described previously [10]. First strand cDNA was
prepared using Superscript reagents (Invitrogen). Quantitative RT-PCRpen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 917
Original articlewas performed using LightCycler 1536 DNA Green Master mix (Roche)
and analyzed on a 1536 LightCycler system (Roche), according to the
manufacturer’s instructions. The list of primers used is presented in
supporting Table 1. Qualitative RT-PCR for CRE expression analysis
was performed using CRE-F AAAATTTGCCTGCATTACCG and CRE-R
ATGTTTAGCTGGCCCAAATG primer pairs generating a 262 nucleo-
tides ampliﬁcation product.
2.6. Insulin secretion and content
EndoC-bH3 cells were seeded onto matrigel- and ﬁbronectin-coated
96 well plates at 7  104 cells/well for un-excised and excised
cells. Three days later, cells were incubated overnight in culture me-
dium that contained 2.8 mM glucose, followed by 60 min incubation in
HEPES-buffered KrebseRinger Buffer (KRB) (115 mmol/l NaCl,
5 mmol/l KCl, 1 mmol/l CaCl2, 1 mmol/l MgCl2, 24 mmol/l NaHCO3,
10 mmol/l HEPES pH 7.4, and 0.2% BSA) that contained 0.5 mM
glucose. At the end of this incubation, stimulated insulin secretion was
measured by static incubation in KRB that contained varying glucose
concentrations for 60 min. Glucose stimulation was performed in the
presence or absence of 500 mM IBMX.
For insulin content measurement, cells were lysed directly in the
culture wells with TETG solution 20 mM Tris pH 8.0; 0.1% Triton X-
100; 1% Glycerol; 137 mM NaCl; 2 mM EGTA and anti-protease tablet
(Roche) for 5 min on ice. The lysate was next centrifuged at 3,000 rpm
for 5 min and stored at 20 C until insulin ELISA assay.
Insulin secretion and intracellular content were measured in duplicate
by ELISA according to manufacturer’s instructions using the human
insulin kit (Mercodia), which does not cross-react with proinsulin.
2.7. Electron microscopy
Cells were ﬁxed with 2.5% Glutaraldehyde and 4% Paraformaldehyde
in Sörensen’s phosphate buffer (pH 7.4) over night. After ﬁxation, cells
were processed for standard Epon embedding as previously described
[19]. Ultrathin sections with a thickness of 70 nm were cut on a Leica
EM6 ultramicrotome and imaged using a Tecnai 12 Biotwin Trans-
mission Electron Microscope (FEI Company, Hillsboro, OR, USA) with a
bottom-mount 2Aw2K F214 CCD camera (TVIPS, Gauting, Germany).
Sixty random images with a size of 8.92 mm  8.92 mm were taken
per condition at a resolution of 4.35 nm/pixel. TEM images were
viewed using FIJI software and insulin secretory granules (SGs) were
scored manually on a Wacom Cintiq 15X LCD tablet (Wacom) to
calculate their number normalized for b-cell cytosolic area.
2.8. Oligonucleotides-based array comparative genomic
hybridization (CGH array)
CGH array was performed using SurePrint G3 Human CGH Bundle
(4  180K) (Agilent) according to manufacturer instructions. Brieﬂy,
1 mg of genomic DNA corresponding to either a human male control
[20], EndoC-bH2 or EndoC-bH3 cells both at passage 40 was frag-
mented by heating at 95 C for 30 min. Fragmented DNAs were
labeled with Cy3 (control DNA) and Cy5 (EndoC-bH2/EndoC-bH3 DNA)
ﬂuorescent dUTP, respectively, using Genomic DNA Enzymatic La-
beling Kit (Agilent Technology). Microcon YM 30 spin columns (Milli-
pore) were used to remove the unincorporated nucleotides and dyes.
Hybridizations of labeled DNA to SurePrint G3 Human CGH Bundle
(4 180K) array (Agilent) were performed in a hybridization oven at 42
C at 20 rpm for 40 h. Hybridized arrays were then washed following the
manufacturer’s instructions. Microarray slides were scanned on a
Nimblegen MS200 Microarray Scanner at a 2 mm resolution. Feature
extraction was done with Cytogenomics Software (Agilent). Extracted
data were imported and analyzed using Nexus 7.0 (Biodiscovery).918 MOLECULAR METABOLISM 4 (2015) 916e925  2015 The Authors. Published by E3. RESULTS
3.1. Production of EndoC-bH3, an excisable human beta cell line
that integrated CRE-ERT2
Our objective was to stably integrate the coding sequence of CRE-ERT2
fusion protein into the genome of EndoC-bH2 cells and to couple such
integration with an antibiotic resistance to select CRE-ERT2 positive
cells. First, EndoC-bH2 sensitivity to neomycin, puromycin or
hygromycin antibiotics was tested. Both puromycin and hygromycin
efﬁciently killed EndoC-bH2 cells within two weeks at 10 mg/ml and
150 mg/ml respectively (not shown). We next constructed a lentiviral
vector expressing both CRE-ERT2 and a Puromycin resistance gene
under the control of CMV and PGK promoters, respectively (Figure 1A).
The vector was used to transduce EndoC-bH2 cells, and we named the
resulting puromycin-selected cells EndoC-bH3. Importantly, the pro-
liferation rate of EndoC-bH3 cells was similar in the presence or
absence of antibiotic (Figure 1B), indicating that the selection does not
hamper the overall growth of the cells. EndoC-bH3 can therefore be
massively ampliﬁed in culture. We next analyzed the chromosomal
stability of EndoC-bH3 cells at passage 40 in comparison to EndoC-
bH2 cells. CGH array proﬁles are almost identical between the two
lines (Figure S1) indicating chromosomal stability following integration
of CRE-ERT2 and antibiotic selection.
3.2. Tamoxifen treatment to achieve efﬁcient activation of
recombinase CRE and excision of SV40LT
Our previous data obtained with EndoC-bH2 indicate that constitutive
CRE expression results in excision of SV40LT [10]. Under such con-
ditions, 21 days after transduction with CRE-expressing lentiviral
vector, proliferation was massively reduced and insulin content
increased. To follow excision efﬁcacy in EndoC-bH3 cells that express
CRE-ERT2, we used 3 readouts: SV40LT expression, incorporation of
EdU for proliferation assessment and insulin content measurement.
Both the concentration of TAM and the duration of treatment were
investigated. Excision efﬁcacy was monitored 21 days after TAM
addition using increasing doses from 1 to 10 mM. TAM was maintained
in the medium for 7 or 21 days (Figure 2A). Importantly, the decrease
in SV40LT expression and EdU incorporation were parallel (Figure 2Be
C). With 7 days treatment, EndoC-bH3 proliferation decreases in a
dose-dependent manner. 11.5% of control untreated cells incorpo-
rated EdU whereas EdU incorporation decreased to 5.1% and 2.2%
with 1 and 10 mM TAM, respectively. With 21 days TAM treatment, all
tested concentrations were equivalent and, on average, only 0.75% of
cells incorporated EdU (Figure 2C). EndoC-bH2 cells that do not contain
an integrated TAM inducible CRE were treated for 7 or 21 days with
either 1 or 10 mM TAM. Such treatments had no effect on cell pro-
liferation (Figure 2D) demonstrating that the massive reduction of
proliferation observed with EndoC-bH3 treated with TAM is due to the
induction of CRE-ERT2 dependent excision.
Following a 7 days TAM treatment, insulin content increased by 12.9
and 17.5 fold when treated with 1e10 mM TAM compared to control
untreated cells (Figure 2E). Such induction was lower than the 23.3
fold induction obtained with 21 days 1 mM TAM treatment (Figure 2E).
Similar high inductions were obtained with 2.5 and 5 mM TAM with 21
days TAM treatment protocol whereas higher doses were less efﬁcient
(Figure 2E). Therefore 1 mM TAM treatment for 21 days represented
the optimal dose that gave the highest outcome to decrease SV40LT
expression, to decrease proliferation and to enhance insulin content.
Finally, the percentage of cells positive for SV40LT protein expression
sharply decreased upon 21 days TAM treatment. Indeed with the
optimal TAM treatment, SV40LT gene expression represents only 8.6%lsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1: Production of EndoC-bH3 cells a Tamoxifen inducible excisable human beta cell line derived from EndoC-bH2. (A) Schematic representation of lentiviral vector
used to produce EndoC-bH3 cells expressing both the TAM inducible form of CRE (CRE-ERT2) and the resistance to puromycin (B) Cells were passaged every week. Ampliﬁcation
index was deﬁned as fold change between the initial number of seeded cells and the one counted one week later before cell passage. Data represent average of ampliﬁcation
index S.E.M. over 10 passages of EndoC-bH3 cells cultured with or without antibiotic (puromycin) selection.of untreated EndoC-bH3 cells (Figure 2B) and the percentage of
SV40LT expressing cells is reduced to 6.7% (Figure 3).
3.3. EndoC-bH3 function after Tamoxifen-mediated transgene
excision
Upon TAM-mediated excision, insulin content in EndoC-bH3 sharply
increased when compared to non-excised cells (Figure 2D). We asked
whether insulin secretion remained responsive to glucose stimulation.
Static glucose-stimulated insulin secretion was assayed on exact same
number of seeded EndoC-bH3 cells that had been treated or not with
TAM for 21 days. As for non-excised EndoC-bH2 cells, glucose did not
stimulate insulin secretion in the absence of IBMX, a phosphodies-
terase inhibitor that increases intracellular levels of cAMP. In the
presence of IBMX, insulin secretion was stimulated 1.8 fold (stimu-
lation index) at 15 mM Glucose compared to 2.8 mM (Figure 4A). When
excised with the optimal TAM treatment deﬁned above, EndoC-bH3
cells responded to glucose both in absence and presence of IBMX with
a stimulation index of 1.8 and 2.6 respectively (Figure 4B). Importantly,
we tested the robustness of both insulin content and glucose
responsive insulin secretion in the 21 days TAM treated cells at
different passages spanning from passage 36 to 60. On average, from
6 independent experiments, insulin content was of 3.1 0.41 mg of
insulin per million cells that represents 10e20% of the content found
in primary human Islets [21]. The stimulation indexes obtained in
absence of IBMX were 1.8 0.35 (S.E.M.) and 2.6 0.15 (S.E.M) in
the presence of IBMX. This indicated that insulin content and secretion
in TAM treated EndoC-bH3 cells were stable over passages. TEM
imaging of TAM treated and non-treated EndoC-bH3 cells corroboratedMOLECULAR METABOLISM 4 (2015) 916e925  2015 The Authors. Published by Elsevier GmbH. This is an o
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treated cells (13.94 1.56 (S.E.M) SGs/10 mm2) compared to non-
treated cells (6.53 0.83 (S.E.M.) SGs/10 mm2) (Student’s t-test p-
value: 4.77325  105) (Figure 5). Also, untreated cells contained
more degradative compartments compared to treated cells.
3.4. Long-term phenotype of Tamoxifen excised EndoC-bH3 cells
We followed TAM-treated EndoC-bH3 cells over time. Total cell
number was counted every 7 days to follow cell growth (Figure 6A).
When TAM was removed at day 21, cell number remained stable for
one additional week (up to day 28 of culture) and then started to in-
crease (Figure 6A, gray line). When TAM was continuously maintained
in the culture medium, cell number remained stable for an additional
week and thus lasted 5 weeks in total (Figure 6A, black line). We next
monitored insulin content over time (Figure 6B). At days 21 and 35,
cells constitutively treated with TAM contained 13.3 and 14.3 times
more insulin that the non-treated cells, respectively. The increase in
insulin content was therefore almost constant during the whole period.
However, it decreased to 7.8 fold by day 49, suggesting that with time,
proliferating non-excised cell that escaped excision, and contained low
levels of insulin, expand. This effect was further enhanced at day 84
(Figure 6B)
We monitored gene expression in TAM-treated EndoC-bH3 cells over
time. Insulin mRNA expression was consistent with insulin content
measurements (Figure 6C). Indeed, insulin mRNA levels in TAM-
treated cells were at least 8 fold higher until day 49 when compared
to non-excised cells (Figure 6C). By day 63 insulin expression levels in
TAM-treated cells returned to the one found in untreated cells. We alsopen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 919
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Figure 2: Deﬁnition of optimal procedure for efﬁcient Tamoxifen treatment of EndoC-bH3. (A) Schematic representation of the experimental optimization procedure for TAM
treatment. (B, C, E) EndoC-bH3 cells were treated for 7 days (white box) or 21 days (Gray box) with TAM. Un-treated cells are represented as hatched box. Proliferation assays and
insulin content measurements were performed at day 21. (B) Effect of TAM treatment on SV40LT gene expression. Quantitative PCR results are representative of 2 independent
experiments performed in triplicates. Data corresponded to average relative expression values normalized to TPB expression S.E.M. (CeD) Effect of TAM treatment on EdU
incorporation by EndoC-bH3 cells (C) or EndoC-bH2 (D) relative to total cell number. EdU was added for 1 h and analysis was performed by FACS. Results are representative of 2
independent experiments performed in duplicates. Data are expressed as average percentage S.E.M. (E) Effect of TAM treatment on insulin content in EndoC-bH3. Data are
expressed as insulin content per million cells S.E.M. of 3 independent wells per condition assayed in triplicates by ELISA.
Original articleassessed in TAM-treated EndoC-bH3 cells the expression of a number
of genes found to be signiﬁcantly increased by constitutive CRE
excision of EndoC-bH2 cells [10]. Their expression was in line with the
above-described observations. Expression levels of beta cells enriched
genes such as IAPP, SLC2A2, KCNJ11, ABCC8, RAB3A, GLIS3 and
PDX1 remained higher in TAM exposed cells compared to un-treated
cells until day 49 and returned to the un-excised level by day 63
(Figure 6C). Moreover, expression of genes involved in cell cycle
control such as Ki67 and CDK1 was massively reduced to 0.17 and
0.16 fold, respectively, in TAM treated cells when compared to un-
treated cells. This reduction was seen only until day 35 (Figure 6D).920 MOLECULAR METABOLISM 4 (2015) 916e925  2015 The Authors. Published by EAs observed in EndoC-bH2 upon CRE excision, CDK4 was also not
modulated with TAM treatment (Figure 6D).
4. DISCUSSION
Collectively, after 21 days TAM treatment, the phenotype of EndoC-
bH3 cells is not signiﬁcantly different from the one previously reported
for EndoC-bH2 expressing constitutive CRE for 21 days [10]
(Supplemental Table S2). This observation is true when monitoring:
(i) cell growth; (ii) SV40LT deletion; (iii) insulin content and insulin
secretion upon glucose stimulation; (iv) expression of importantlsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 4: Glucose responsive insulin secretion in EndoC-bH3 following treatment with Tamoxifen. EndoC-bH3 were treated or not for 21 days with 1 mM TAM. (A) Glucose
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Figure 5: TEM analysis of treated and untreated EndoC-bH3. Non-treated and treated EndoC-bH3 cells were analyzed after Epon embedding and ultrathin sectioning. (A) Non-
treated EndoC-bH3, inset: detail of insulin SGs, (B) TAM-treated EndoC-bH3, inset: detail of insulin SGs. Scale bar: 2 mm. Labeling key: Nuc, nucleus; Mito, mitochondria; SG,
secretory granules; arrowheads, degradative compartments.
Original articlefunctional beta cell and proliferation markers. Thus, by developing this
simple and efﬁcient TAM treatment procedure, non-proliferative
functional human beta cells can now be produced in large quantity.
It has been reported that TAM could have proapoptotic effect in vivo on
mouse beta cells [22]. We addressed cell survival upon continuous
exposure to TAM (1 mM and 10 mM) for 21 days in EndoC-bH2, the cell
line from which EndoC-bH3 was derived, and in which the CRE-ERT2
transgene is absent. We did not observe any difference in cell growth
between treated and non-treated cells (Supplemental Figure S2) nor at
the level of EdU incorporation (Figure 2C) even at the high dose of
10 mM. Our results thus indicate that continuous treatment with TAM
does not interfere with cell survival. Morphometry of TEM images
revealed a 2.15 fold increase in the number of insulin SGs in TAM
treated vs. non-treated cells. Treated cells contained instead fewer
degradative compartments compared to non-treated cells, possibly
due to the switch from proliferation to SG production.
In previous work, when CRE was constitutively expressed in EndoC-
bH2 cells, immortalizing transgenes were excised in the vast majority
of cells [10]. We hypothesized that the remaining non-excised cells
had escaped initial transduction with CRE-expressing lentiviral vector.
Therefore, it was reasonable to envisage that adding an antibiotic
selection system in the integrative vector expressing CRE-ERT2 would
allow selection of 100% CRE-ERT2 positive cells and increase efﬁ-
ciency of immortalizing transgene excision. When dose and duration
of TAM treatment were optimized, we observed that, although cells
were grown under continuous puromycin selection pressure, efﬁcacy
of excision was not complete since some cells remained in a prolif-
erative state (Figure 2A) and scattered cells still expressed SV40LT
(Figure 3). Two main reasons could explain this counterintuitive
observation of incomplete CRE mediated recombination. First, TAM-
inducible CRE recombination has been extensively used in vivo in
transgenic models and efﬁcacy of recombination is highly variable
depending on recombinase expression levels [23,24] and genome
availability of LoxP sites [25e27]. Since, EndoC-bH3 cells were
generated from lentiviral mediated transduction of EndoC-bH2 cells
without further clonal selection, the variability of CRE-ERT2 integration
sites may be responsible for inter-cellular variability of recombinase
expression. Such heterogeneity could sustain the fact that a small cell922 MOLECULAR METABOLISM 4 (2015) 916e925  2015 The Authors. Published by Epopulation was unable to achieve efﬁcient excision of immortalizing
transgenes. Second, the lentiviral construct used to generate EndoC-
bH3 cells is composed of two separate transcription units. Specif-
ically, in the same integrated fragment, CRE-ERT2 is expressed under
the control of the CMV promoter and the resistance to puromycin
under a different promoter (PGK). Thus, with time in culture, CRE-
ERT2 transcription could be reduced or extinguished, while puromy-
cin resistance remains selected by the antibiotic in the culture me-
dium. Of note, CMV promoters are known to be subject to extinction
with time [17,28e30].
While the vast majority of the cells efﬁciently recombine the loxP sites
and excise the immortalizing transgenes, rare cells escape this pro-
cess. Our data indicate that the overall composition of the cell pop-
ulations (unexcised vs excised cells) is maintained relatively constant
for 49 days with the majority of cells baring a non-proliferative state
with high insulin content. However, with time, the proliferative
advantage of non-excised cells will result in a time dependent modi-
ﬁcation of the relative proportion of both cell populations and by day
66, the cell population is mainly composed of cells that behave like
proliferating, untreated EndoC-bH3. Interestingly, although such cells
were proliferating in the presence of TAM, after 66 and 119 days of
TAM treatment, they still expressed CRE-ERT2 mRNA (Figure S3),
suggesting that they were unable to activate loxP recombination to
efﬁciently remove immortalizing transgenes. The above-described
experiments were performed on non-clonal cell populations. Ampli-
fying cell subclones could represent a way to select lines with further
increased loxP recombination efﬁcacy. Furthermore, complete removal
of proliferating SV40LT positive cells could be achieved through
counter-selection using a suicide gene approach such as thymidine
kinase in the presence of Gancyclovir [31].
5. CONCLUSION
Altogether, we have produced a novel human beta cell line derived
from EndoC-bH2 cells [10] that contains ﬂoxed immortalizing trans-
genes and an integrated TAM inducible form of CRE recombinase.
Such line can be massively ampliﬁed followed by immortalizing
transgenes removal by simple addition of TAM, giving rise to non-lsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 6: Long-term phenotype of Tamoxifen treated EndoC-bH3. (A) Cell growth monitoring over time (every 7 days) during 63 days. TAM treatment was either stopped at
day 21 (in gray), or continued during the whole experiment (in black). (B) Insulin content was determined in EndoC-bH3 cells continuously treated with TAM and compared to
untreated cells. Analysis was performed every second week, starting 21 days after initial TAM treatment. Data are expressed as fold change over untreated cells (dotted line) of
insulin content S.E.M. of 3 independent wells per condition assayed in replicates by ELISA. (CeD) Gene expression by quantitative RT-PCR was determined in EndoC-bH3 cells
that were continuously treated with TAM and compared to untreated cells. Analysis was performed every second week, starting 21 days after initial TAM treatment. Data are
expressed as fold change of mRNA expression relative to TBP S.E.M. of 3 independent RNA preparations assayed in triplicates.
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Original articleproliferating functional human beta cells. This new line offers simple
and efﬁcient procedure to mass produce non-proliferative human beta
cells that can maintain a stable phenotype for 5 weeks in culture thus
providing a powerful tool for large-scale drug discovery.
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